Nervous Disorder TRIZ Cases

SRRD protein acts as a molecular chaperone to stabilize misfolded proteins and reduce aggregation in neurodegenerative disease models.

Antibodies targeting unique IL-17F epitopes resolve cross-reactivity with IL-17A, reducing pro-inflammatory cytokine production by up to 100%.

A monoclonal antibody binds the voltage sensor paddle of Nav1.9 channels to block sodium ion entry and inhibit pain signaling pathways.

ERK1-derived peptides inhibit MAPK3 kinase to facilitate selective nuclear ERK signalling, preventing neurodegeneration and memory deficits.

Heat treatment denatures fibrinogen in pooled platelet lysate to preserve neurotrophic factors.

Segmented PCR primers detect specific somatostatin receptor isoforms, resolving the trade-off between measurement precision and adaptability.

Arylpiperazine ligands target dopamine D3 receptors selectively, avoiding side effects from non-specific D2 activation.

AAV-delivered AADC polynucleotides sustain dopamine synthesis locally, resolving motor fluctuations and hallucinations from systemic high-dose treatments.

Ganoderma immunomodulatory protein crosses the placental barrier to protect embryos from particulate matter exposure.

Oral administration of SCFAs and carnitines restores microbial diversity, reducing withdrawal symptoms without causing treatment dependence.

A tetrapeptide medicinal product reduces pain intensity through selective mu1-opioid receptor activation.

Recombinant felinized antibodies sequester feline NGF to block TrkA and p75 receptors, eliminating chronic pain without inducing neutralizing immune responses.

Pterosin compounds extracted from bracken ferns inhibit key enzymes for brain disease treatment.

Tempol and cholecalciferol compositions reduce cerebral cavernous malformation lesion counts, addressing surgical inaccessibility.

Peptide linkers stabilize CD3-CD137 fusion proteins, reducing renal clearance and extending half-life while preventing T cell hyperactivation.

Merges systemic analgesics with artificial sensory experiences to reduce opioid dosage while addressing psychological pain components.

Systemic KCNQ potassium channel openers enhance neuronal currents to reduce excitability, preventing post-traumatic seizures and cognitive dysfunction.

Targeted GBX2, CDX2, and HOXA1 knockouts restrict lineage potential to resolve purity-reliability contradictions in dopaminergic neuron production.

A rivastigmine transdermal patch uses a silicone acrylic hybrid polymer adhesive layer to deliver the drug continuously for 24 hours.

Dispersing fine sugar particles in an organic solvent reduces the sticky sensation of water-soluble polymers while maintaining sufficient film strength.

Esterified beta-hydroxybutyrate compounds release ketone bodies to overcome insufficient cognitive benefits from medium-chain triglycerides.

A composition using specific transcription factors to induce direct transdifferentiation of somatic cells into oligodendrocyte progenitor cells.

Combining alpha-lipoic acid with honokiol in specific weight ratios creates a synergistic pharmaceutical composition.

Inhaled xenon gas targets NMDA receptors to reduce levodopa-induced dyskinesia amplitude and duration without dopaminergic interference.

Humanizing rodent-derived anti-NGF antibodies eliminates the human anti-murine immune response while maintaining high-affinity binding and therapeutic efficacy.

Modifying amino acids at positions 8, 9, and 10 boosts biological activity, lowering clinical doses while reducing side effects.

Neural extracellular vesicles bypass stem cell risks like teratoma formation while reducing infarct size and improving functional outcomes.

Fused heteroaryl compounds resolve selectivity challenges by targeting abnormal late sodium currents to treat neurological disorders.

Circularized peptide immunogens preserve native epitope conformations to generate highly specific antibodies against Fc receptors.

NKCC1 inhibitors reduce intracellular chloride to restore GABA polarity, resolving cognitive deficits in Down syndrome models.

Agents utilize RECK and GPR124 to selectively activate Wnt7 signaling, reducing cross-reactivity with other Frizzled pathways.

Gastroretentive acamprosate formulations segment dosing schedules to improve bioavailability and reduce side effects.

Bicyclic aryl compounds inhibit autotaxin to block lysophosphatidic acid production, enabling remyelination in demyelination disorders.

Structural parameter changes at the cyclopentene ring create mechanism-based inactivators that reduce off-target effects and side effects of vigabatrin.

Monoclonal antibodies 1A9 and 2C3 bind specifically to soluble Aβ oligomers without recognizing monomers.

Zn(II)-curcumin solid dispersions with PVP carrier overcome poor water solubility and low oral absorption of curcumin.

Integrin αvβ8 antagonist selectively blocks TGFβ activation in target tissues, avoiding systemic side effects from global inhibition.

Nefopam treats sickle cell pain while reducing opioid side effects and dependency risks.

Novel antibodies target DICAM to block inflammatory cell migration across the blood-brain barrier.

Extracellular vesicles derived from human induced pluripotent stem cell neural stem cells modulate microglial function and reduce neuroinflammation.

Inhibitory nucleic acids reduce Ataxin-2 protein levels to alleviate progressive neurodegeneration in SCA2 and ALS models.

Pharmaceutical agents target NF-kB expression in microglia to protect motor neurons from death.

Agarophyton chilensis extract enriched with free fatty acids activates PPARγ receptors to provide neuroprotective effects.

Reduced sumoylation in a modified EKLF polypeptide restores SOD1 function to reverse neurodegeneration and improve motor skills in ALS models.

Phenylsulfamoyl benzamide derivatives target bradykinin B1 receptors to reduce side effects from non-specific binding.

Fully human anti-PSMA antibodies bind prostate-specific membrane antigen to deliver therapeutic payloads, reducing toxicity to normal tissues.

Controlled crystallization yields polymorphic rivastigmine hydrogentartrate forms that increase dissolution rates while maintaining chemical stability.

A fixed 5:1 memantine to donepezil ratio reduces dosing frequency while maintaining efficacy for Alzheimer's disease.

Antibodies targeting Activin A inhibit signaling without affecting other ActRIIB ligands, resolving off-target efficacy issues in muscle disorders.